Lysine methylation modulates diverse biological processes and is catalyzed by SET domain methyltransferases such as the SMYDs (SMYD1-5), which possess a SET domain split by a MYND motif. Through association with NCoR, the H4 Lys20 methyltransferase activity of SMYD5 represses inflammation by restricting TLR-4 mediated expression in macrophages, yet biochemical and structural features required for SMYD5 methylation activity remain elusive. To determine how SMYD5 catalyses methylation, crystallization screens were conducted with SMYD5 in complex with the co-factor AdoMet and histone H4. Screens yielded lead conditions but no crystals. To determine the motif recognized by SMYD5 and decipher its methylome, peptide arrays were conducted to produce a methylation motif used to identify putative substrates. Surprisingly, arrays revealed that substitution of Lys16, not Lys20, is detrimental to SMYD5 activity. Further enzymatic assays are required to determine if SMYD5 methylates residues other than Lys20 on the H4 tail, or if structural determinants or interacting partners restrict methylation of target lysines.

As phosphorylation represents the pivotal mechanism for regulation of biological processes, kinases belong to one of the most biologically significant enzyme classes. The development of analytical techniques for characterization of kinase activity, in particular at a global scale, is a central priority for proteomic and cell biology researchers. In order to facilitate global analysis of cellular phosphorylation, a new paradigm of microarray technology which focuses on analysis of total cellular kinase activity, kinome, has emerged in the past few years. As the specificity of many kinases is dictated primarily by recognition of residues immediately surrounding the site of phosphorylation a logical methodology is to employ peptides representing these immediate sequences as experimental substrates. Microarray chips carrying hundreds of such substrate targets have been developed for human kinome analysis, however, lack of similar tools for species outside research mainstream has limited kinome analysis in these species.<p> Based on sequence alignment of orthologous phosphoproteins from mammalian species, conservation of amino acid identity is reported to be 80 %. Accordingly, the potential exists to utilize phosphorylation sequence databases to extrapolate phosphorylation sites in other species based on their genomic sequence information. Peptides representing these proposed phosphorylation sites can then be utilized as substrates to quantify the activity of the corresponding kinase. Based on these principles, a bovine microarray of 300 unique peptide targets was constructed. The bovine phosphorylation targets were selected to represent a spectrum of cellular events but with focus on processes related to innate immunity. Initial application and validation of the bovine peptide arrays was carried out for kinome analysis of bovine blood monocytes stimulated with either lipopolysaccharide (LPS) or CpG-ODNs; ligands for Toll-like receptors (TLR) 4 and 9, respectively. The arrays confirmed activation of the known TLR signaling pathway as well as identifying receptor-specific phosphorylation events. Phosphorylation events not previously attributed to TLR activation were also identified and validated by independent bioassays. This investigation offers insight into the complexity of TLR signaling and more importantly verifies the potential to use bioinformatics approaches to create tools for species-specific kinome analysis based on genomic information.

As phosphorylation represents the pivotal mechanism for regulation of biological processes, kinases belong to one of the most biologically significant enzyme classes. The development of analytical techniques for characterization of kinase activity, in particular at a global scale, is a central priority for proteomic and cell biology researchers. In order to facilitate global analysis of cellular phosphorylation, a new paradigm of microarray technology which focuses on analysis of total cellular kinase activity, kinome, has emerged in the past few years. As the specificity of many kinases is dictated primarily by recognition of residues immediately surrounding the site of phosphorylation a logical methodology is to employ peptides representing these immediate sequences as experimental substrates. Microarray chips carrying hundreds of such substrate targets have been developed for human kinome analysis, however, lack of similar tools for species outside research mainstream has limited kinome analysis in these species.<p> Based on sequence alignment of orthologous phosphoproteins from mammalian species, conservation of amino acid identity is reported to be 80 %. Accordingly, the potential exists to utilize phosphorylation sequence databases to extrapolate phosphorylation sites in other species based on their genomic sequence information. Peptides representing these proposed phosphorylation sites can then be utilized as substrates to quantify the activity of the corresponding kinase. Based on these principles, a bovine microarray of 300 unique peptide targets was constructed. The bovine phosphorylation targets were selected to represent a spectrum of cellular events but with focus on processes related to innate immunity. Initial application and validation of the bovine peptide arrays was carried out for kinome analysis of bovine blood monocytes stimulated with either lipopolysaccharide (LPS) or CpG-ODNs; ligands for Toll-like receptors (TLR) 4 and 9, respectively. The arrays confirmed activation of the known TLR signaling pathway as well as identifying receptor-specific phosphorylation events. Phosphorylation events not previously attributed to TLR activation were also identified and validated by independent bioassays. This investigation offers insight into the complexity of TLR signaling and more importantly verifies the potential to use bioinformatics approaches to create tools for species-specific kinome analysis based on genomic information.

abstract: Peptide microarrays have been used in molecular biology to profile immune responses and develop diagnostic tools. When the microarrays are printed with random peptide sequences, they can be used to identify antigen antibody binding patterns or immunosignatures. In this thesis, an advanced signal processing method is proposed to estimate epitope antigen subsequences as well as identify mimotope antigen subsequences that mimic the structure of epitopes from random-sequence peptide microarrays. The method first maps peptide sequences to linear expansions of highly-localized one-dimensional (1-D) time-varying signals and uses a time-frequency processing technique to detect recurring patterns in subsequences. This technique is matched to the aforementioned mapping scheme, and it allows for an inherent analysis on how substitutions in the subsequences can affect antibody binding strength. The performance of the proposed method is demonstrated by estimating epitopes and identifying potential mimotopes for eight monoclonal antibody samples. The proposed mapping is generalized to express information on a protein's sequence location, structure and function onto a highly localized three-dimensional (3-D) Gaussian waveform. In particular, as analysis of protein homology has shown that incorporating different kinds of information into an alignment process can yield more robust alignment results, a pairwise protein structure alignment method is proposed based on a joint similarity measure of multiple mapped protein attributes. The 3-D mapping allocates protein properties into distinct regions in the time-frequency plane in order to simplify the alignment process by including all relevant information into a single, highly customizable waveform. Simulations demonstrate the improved performance of the joint alignment approach to infer relationships between proteins, and they provide information on mutations that cause changes to both the sequence and structure of a protein. In addition to the biology-based signal processing methods, a statistical method is considered that uses a physics-based model to improve processing performance. In particular, an externally developed physics-based model for sea clutter is examined when detecting a low radar cross-section target in heavy sea clutter. This novel model includes a process that generates random dynamic sea clutter based on the governing physics of water gravity and capillary waves and a finite-difference time-domain electromagnetics simulation process based on Maxwell's equations propagating the radar signal. A subspace clutter suppression detector is applied to remove dominant clutter eigenmodes, and its improved performance over matched filtering is demonstrated using simulations. / Dissertation/Thesis / Doctoral Dissertation Electrical Engineering 2014

Capillary Morphogenesis Gene 2 (CMG2) is a type I transmembrane, integrin-like receptor. It was originally identified as one of several genes upregulated during capillary formation. It was subsequently identified as one of two physiological anthrax toxin receptors, where CMG2 serves as a cell-surface receptor for anthrax toxin and mediates entry of the toxin into cells via clathrin-dependent endocytosis. Additionally, loss-of-function mutations in CMG2 cause the genetic disorder hyaline fibromatosis syndrome (HFS), where the core symptom is dysregulation of extracellular matrix homeostasis (ECM), including excessive accumulation of proteinaceous hyaline material; HFS clearly indicates that CMG2 plays an essential function in ECM homeostasis and repair. Most often, these situational roles have been evaluated as separate intellectual and experimental entities; consequently, whereas details have emerged for each respective situational role, there has been little attempt to synthesize knowledge from each situational role in order to model a holistic map of CMG2 function and mechanism of action in normal physiology.The work presented in this thesis is an example of such a synthesis. Interactions between CMG2 and type IV collagen (Col IV) were evaluated, to better understand this putative interaction and its effect on CMG2 function in angiogenesis. Using an overlapping library peptide array of the Col IV α1 and α2 chains, it was found that CMG2-binding peptides were enriched within the NC1 domains. This finding was corroborated via another epitope mapping peptide array, where we found a major epitope for CMG2-binding within the α2 NC1 domain (canstatin). Identification of CMG2 interactions with Col IV NC1 domains (including canstatin) was both surprising and intriguing, as these domains are potent endogenous inhibitors of angiogenesis. To further evaluate the physiological relevance of interactions with Col IV NC1 domains, a canstatin-derived peptide from the original array was synthesized and used for further studies. This peptide (here known as S16) binds with high affinity (KD = 440 ± 160 nM) to the extracellular, ligand-binding CMG2 vWA domain; specificity was confirmed through competition studies with anthrax toxin PA, and through demonstration of divalent cation-dependent binding. CMG2 was found to be the relevant endothelial receptor for S16. CMG2 in fact mediates endocytic uptake of peptide S16, as demonstrated by flow cytometry, and colocalization studies. S16 further inhibits migration of endothelial cells. These findings demonstrate that CMG2 is a functional receptor for Col IV NC1 domain fragments. CMG2 may exert a pro-angiogenic effect through endocytosis and clearance of anti-angiogenic NC1 domain fragments. Additionally, this is the first demonstration of CMG2-mediated uptake of an endogenous matrix fragment, and suggests a mechanism by which CMG2 regulates ECM and basement membrane homeostasis, thereby establishing a functional connection between the receptor's role in matrix biology and angiogenesis.

Antibodies play an important role in the natural immune response to invading pathogens. The strong and specific binding to their antigens also make them indispensable tools for research, diagnostics and therapy. This thesis describes the development of methods for characterization of an- tibody specificity and the use of these methods to investigate the polyclonal antibody response after immunization. Paper I describes the development of an epitope-specific serum fractionation technique based on epitope map- ping using overlapping peptides followed by chromatographic separation of polyclonal serum. This technique together with another epitope mapping technique based on bacterial display of protein fragments were then used to generate antibody sandwich pairs (Paper I), investigate epitope variations of repeated immunizations (Paper II) and to determine the ratio of antibodies targeting linear and conformational epitopes of polyclonal antibodies (Paper III). Paper IV describes the optimization of in situ-synthesized high-density peptide arrays for epitope mapping and how different peptide lengths influ- ence epitope detection and resolution. In Paper V we show the development of planar peptide arrays covering the entire human proteome and how these arrays can be used for epitope mapping and off-target binding analysis. In Paper VI we show how polyclonal antibodies targeting linear epitopes can be used for peptide enrichment in a rapid, absolute protein quantification protocol based on mass spectrometry. Altogether these investigations demonstrate the usefulness of peptide arrays for fast and straightforward characterization of antibody specificity. The work also contributes to a deeper understanding of the polyclonal anti- body response obtained after immunization with recombinant protein frag- ments. / <p>QC 20141111</p>

This thesis, based on five research papers, presents results from development and evaluation ofmethods for identifying the interaction site of antibodies on their antigens and the functional investigation of these in different assays. As antibodies have proven to be invaluable tools in diagnostics, therapy and basic research, the demand of characterizing these binding molecules has increased. Techniques for epitope mapping in a streamlined manner are therefore needed, particularly in high throughput projects as the Human Protein Atlas that aims to systematically generate two antibodies with separate epitopes towards all human proteins.  In paper I we describe an approach to map the epitopes of polyclonal and monoclonal antibodies for the first time using staphylococcal display. This method was combined with peptide scanning and alanine scanning using suspension bead arrays, to create a streamlined approach of highresolution characterization of epitopes recognized by antibodies as demonstrated in paper II. Single epitopes were identified for the monoclonal antibodies and several (one to five) separate epitopes scattered throughout the antigen sequence were determined for each polyclonal antibody. Further, antibodies of different species origin showed overlapping binding epitopes. In paper III we studied the epitope patterns of polyclonal antibodies generated with the same antigen in different animals. Although common epitope regions could be identified the exact epitope pattern was not repeated, as some epitopes did not reoccur in the repeated immunizations. In paper IV, a potential biomarker for colon cancer, RBM3, was investigated using validated antibodies by epitope mapping and siRNA analysis. Finally, in paper V, a method for generating epitope-specific antibodies based on affinity purification of a polyclonal antibody is described. The generated antibodies were used in several immunoassays and showed a great difference in functionality. Paired antibodies with separate epitopes were successfully generated and could be used in a sandwich assay or to validate each other in immunohistochemistry. Taken together, in these studies we have demonstrated valuable concepts for the characterization of antibody epitopes. / QC 20120111

abstract: The healthcare system in this country is currently unacceptable. New technologies may contribute to reducing cost and improving outcomes. Early diagnosis and treatment represents the least risky option for addressing this issue. Such a technology needs to be inexpensive, highly sensitive, highly specific, and amenable to adoption in a clinic. This thesis explores an immunodiagnostic technology based on highly scalable, non-natural sequence peptide microarrays designed to profile the humoral immune response and address the healthcare problem. The primary aim of this thesis is to explore the ability of these arrays to map continuous (linear) epitopes. I discovered that using a technique termed subsequence analysis where epitopes could be decisively mapped to an eliciting protein with high success rate. This led to the discovery of novel linear epitopes from Plasmodium falciparum (Malaria) and Treponema palladium (Syphilis), as well as validation of previously discovered epitopes in Dengue and monoclonal antibodies. Next, I developed and tested a classification scheme based on Support Vector Machines for development of a Dengue Fever diagnostic, achieving higher sensitivity and specificity than current FDA approved techniques. The software underlying this method is available for download under the BSD license. Following this, I developed a kinetic model for immunosignatures and tested it against existing data driven by previously unexplained phenomena. This model provides a framework and informs ways to optimize the platform for maximum stability and efficiency. I also explored the role of sequence composition in explaining an immunosignature binding profile, determining a strong role for charged residues that seems to have some predictive ability for disease. Finally, I developed a database, software and indexing strategy based on Apache Lucene for searching motif patterns (regular expressions) in large biological databases. These projects as a whole have advanced knowledge of how to approach high throughput immunodiagnostics and provide an example of how technology can be fused with biology in order to affect scientific and health outcomes. / Dissertation/Thesis / Doctoral Dissertation Biological Design 2014

CD2AP is a member of the CD2AP/CIN85 family of adaptors and involved in several cellular processes, such as kidney podocyte development, actin mediated membrane trafficking and T cell activation. It contains three SH3 domains whose binding properties and interaction partners remain largely unexplored. The CD2AP SH3 interaction with the novel partner Rab5-activating GEF RIN3 was studied extensively by isothermal titration calorimetry (ITC), peptide scanning arrays, mutagenesis and X-ray crystallography. Mapping of the interaction regions showed that human RIN3 contains two binding sites for the CD2AP SH3 domains. From these studies, the CD2AP SH3 recognition motif P-x-P/A-x-x-R emerged. Two crystal structures (1.65 &Aring; and 1.2 &Aring;) of the SH3 1 and SH3-2 domains in complex with RIN3 epitopes 1 and 2 respectively revealed that these residues serve as anchoring points. With the aid of bioinformatics tools, this motif was used to conduct a peptide array-based screen for additional signalling partner candidates. One of the hits was the Arf-GAP ARAP1. ITC data indicate that the three SH3 domains differentially recognise three ARAP1 epitopes, with the first ARAP1 epitope binding to SH3-2 in the nanomolar range. A crystal structure (1.6 &Aring;) of the SH3-2 domain in complex with the first ARAP1 epitope implicates two additional anchoring residues that extend beyond the PPII helical region of the canonical motif. The CD2AP/ARAP1 interaction was confirmed in podocytes and cancer cells at the endogenous protein level. Even though RIN3 and ARAP1 are involved in membrane trafficking, a direct link to CD2AP had not been reported before. Other candidates from the peptide array analyses were also investigated by ITC. In conclusion, this study led to the elucidation of the CD2AP SH3-1 and SH3-2 domain binding signatures and the identification of putative novel binding partners for all three SH3 domains. Lastly, insight was gained into the binding preferences of CD2AP SH3-3.

Ein charakteristisches Merkmal des humoralen Immunsystems ist die Produktion vieler verschiedener Antikörper. Geläufige diagnostische Tests für den Nachweis von Krankheit-spezifischen Serumantikörpern nutzen Antigene zum Nachweis der Krankheit via Antikörperbindung. Derartige diagnostische Tests setzen jedoch die Kenntnis von Krankheit-spezifischen Antigenen voraus. Die vorliegende Arbeit berücksichtigt die unterschiedlichen Bindungsreaktivitäten ganzer Antikörperrepertoires verschiedener Gruppen von Individuen. Dazu werden die Serumantikörperbindungen gegenüber Zufallsbibliotheken gemessen. Die Moleküle dieser beliebigen Bibliotheken müssen keine Verwandtschaft zu den Antigenen der Krankheit haben. Mit modernen Herstellungsverfahren von Peptidarrays auf Glasträgern können mit einmal synthetisierten Peptiden hunderte von Träger-Replikas produziert werden. Die Suche nach hochaffinen Bindern zur Diagnose von Krankheiten mit unbekannten Antigenen oder mit Kreuzreaktivitäten zwischen gesunden und kranken Individuen könnte überflüssig werden. Gestützt auf die beschriebenen Voraussetzungen zeigt die vorliegende Arbeit, dass die Messung von Serumantikörper-Bindungen gegenüber Peptidbibliotheken mit zufälligen Sequenzen die Unterscheidung zwischen Gruppen von gesunden und kranken Individuen für unterschiedliche Krankheiten ermöglicht. Eine unerwartet kleine Anzahl von Peptiden ist ausreichend für eine zuverlässige Vorhersage der untersuchten Gruppen. Der unvoreingenommene Ansatz ermöglicht eine ebenso gute Unterscheidung von gesund und krank, wie sie auch mit voreingenommenen Bibliotheken gezeigt worden sind. Wir vermuten, dass der vorliegende Ansatz ein wichtiger Schritt in Richtung zuverlässiger Diagnose darstellt, insbesondere für Krankheiten mit noch unbekannten Antigenen. Ausserdem bietet die hohe Spezifizität der Detektone und deren kleinen Mitgliederzahl eine Grundlage für die gleichzeitige Diagnose von verschiedenen Krankheiten auf einem einzigen Peptid-Mikroarray. / A characteristic trait of the humoral immune system is the production of lots of different antibodies. Commonly used diagnostic tests for the detection of disease-specific serum-antibodies successfully exploit these antibody reactivities against disease eliciting antigens. Such diagnostic tests do however need the knowledge of disease specific antigen as a prerequisite. The presented work looks at the binding reactivities of whole antibody repertoires of different groups of individuals. Therefore the binding of serum-antibodies are measured against arbitrary probe molecule libraries. The arbitrary molecules of such libraries do not need to be related to the antigens of the disease to be diagnosed. Modern synthesis and printing processes of peptides on glass chips arrays allow the production of hundreds or peptide-chip replicas with small amounts of uniquely synthesized peptides. The search for high-affinity binders for the diagnosis of diseases with no known antigens might become redundant. Based on the described premises the presented work demonstrates the differentiation of different diseases by means of antibody serum reactivity differences towards arbitrary peptide libraries between healthy and diseased individuals. The number of peptides necessary for reliable prediction of the investigated groups of individuals are unanticipated small. The unbiased approach of the library design works as well as it possibly could with intended libraries, like whole-proteome arrays, used in recent other works. We presume our approach to be an important step forward towards reliable diagnosis, in particular for diseases caused by yet unknown antigens. Furthermore, the high specificity of the detectons and their smallness in size might provide a basis for simultaneous diagnosis of various diseases on a single peptide microarray.